Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial

Authors :: Mark Jones
Gagandeep Kang
Thomas L Snelling
Vivekanand Jha
Vinay Rathore
Stephane Heritier
Meg Jardine
Kapil Soni
James Totterdell
Sradha Kotwal
Guy Thwaites
Cheryl Jones
Carol Pollock
Richard Haynes
Katrina Diamante
Abhinav Bassi
Nikita Bathla
Natalie Staplin
Arlen Wilcox
Ashpak Bangi
Gregory Fox
Atul Jindal
Rui Xie
Daniel Vincent O'Hara
Sanjay D'Cruz
Manish Kumar Jain
Louise Burrell
Sharifah Faridah Syed Omar
Gerard Estivill Mercade
Aishwarya Nair
Annelise Decaria
Nicola Abignano
Sabah Siddiqui
Suprava Patel
Anjulata Sahu
Yasmeen Shaikh
Madhavender Jain
Shivam R Kanje
Sanjeev Kumar Vimal
K. Kalyan Chakravarthy
P. Sathish Babu
Yuvraj Singh Cheema
Merlin Moni
Sivapriya G Nair
Source :: BMJ Open, Vol 14, Iss 10 (2024)
Publication Year :: 2024
Publisher :: BMJ Publishing Group, 2024.
Abstract: Objective To determine whether a chemokine receptor type 2 antagonist, DMX-200 (repagermanium), in combination with an angiotensin receptor blocker, candesartan, improves clinical outcomes in people with COVID-19.Design Prospective, multicentre, double-blind, placebo-controlled trial.Setting Ten acute care hospitals in India.Participants Adults

Full Text Access

Tools